Barclays PLC Acquires 64,101 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

Barclays PLC increased its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 70.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 155,179 shares of the biotechnology company’s stock after purchasing an additional 64,101 shares during the period. Barclays PLC owned approximately 0.18% of Anavex Life Sciences worth $882,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Orion Capital Management LLC grew its position in shares of Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after buying an additional 10,000 shares during the period. Geode Capital Management LLC boosted its stake in Anavex Life Sciences by 2.8% during the third quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock worth $10,699,000 after acquiring an additional 51,946 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in Anavex Life Sciences in the third quarter worth $102,000. BNP Paribas Financial Markets grew its holdings in Anavex Life Sciences by 97.0% in the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 7,421 shares during the period. Finally, Nwam LLC bought a new stake in Anavex Life Sciences in the third quarter valued at $5,172,000. 31.55% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on AVXL shares. HC Wainwright increased their price objective on shares of Anavex Life Sciences from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, December 26th. D. Boral Capital reissued a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research note on Monday.

Anavex Life Sciences Stock Performance

AVXL stock opened at $10.47 on Wednesday. The business has a 50-day simple moving average of $9.55 and a two-hundred day simple moving average of $7.06. The company has a market capitalization of $888.02 million, a P/E ratio of -20.94 and a beta of 0.70. Anavex Life Sciences Corp. has a 52-week low of $3.25 and a 52-week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.03. As a group, sell-side analysts forecast that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current fiscal year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.